EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY

Severine Vermeire  ¹     David T. Rubin  ²     Mamoru Watanabe  ³     Stefan Schreiber  ⁴     Rajiv Mehta  ⁵     Xavier Roblin  ⁶     Mark C. Genovese  ⁷     Tomasz Masior  ⁸     Rahul Barron     Franck-Olivier Le Brun     Silvio Danese  ^{9, 10    
1} UZ Leuven, Leuven, Belgium
² Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, United States
³ Tokyo Medical and Dental University, Tokyo, Japan
⁴ University Hospital Schleswig-Holstein, Kiel, Germany
⁵ Surat Institute of Digestive Sciences Hospital, Surat, India
⁶ University Hospital of Saint-Étienne, Saint-Étienne, France
⁷ Gilead Sciences Inc., Foster City, United States
⁸ Galapagos GmbH, Basel, Switzerland
⁹ IRCCS Hospital San Raffaele, Milan, Italy
¹⁰ Vita-Salute San Raffaele University, Milan, Italy

Topic
Endoscopy, IBD

Session
Hit the road JAK: Part 1

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)